Monoclonal antibodies

Zymeworks Appoints Chief People Officer

Retrieved on: 
Wednesday, October 16, 2019
Biotechnology, Pharmaceutical, Health, Clinical trials, Articles, Life sciences, Biotechnology, Medicine, Monoclonal antibodies, Immunology, Antibody-drug conjugate, Bispecific monoclonal antibody, Chief human resources officer, Biopharmaceutical

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn ODriscoll to the executive team as Chief People Officer (CPO).

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the appointment of Kathryn ODriscoll to the executive team as Chief People Officer (CPO).
  • In her new role as Zymeworks CPO, she will be responsible for growing and developing its highly diverse and skilled workforce.
  • Formerly she was the Vice President and Chief Human Resources Officer at PATH, an international leader in global health innovation, where she led a human resources team that had impact in over 50 countries.
  • Zymeworks second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks proprietary ZymeLink cytotoxic payload.

Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against MacroGenics, Inc. (MGNX) and November 12 Deadline

Retrieved on: 
Wednesday, October 16, 2019
Legal, Professional services, Life sciences, Articles, Biotechnology, Margetuximab, Biopharmaceutical, Monoclonal antibodies

The lead plaintiff deadline is November 12, 2019.

Key Points: 
  • The lead plaintiff deadline is November 12, 2019.
  • MacroGenics is a clinical stage biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of cancer.
  • The lawsuit alleges that, throughout the Class Period, defendants misled investors regarding the results of the Companys SOPHIA clinical trial evaluating product candidate margetuximab.
  • The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

Retrieved on: 
Tuesday, October 15, 2019
Health, Monoclonal antibodies, Drugs, Genmab, Orphan drugs, Daratumumab, Johnson & Johnson, Janssen Biotech, CD38, Janssen

Genmab will receive royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab will receive royalties on worldwide net sales from Janssen Biotech, Inc.
    Copenhagen, Denmark; October 15, 2019 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 765 million in the third quarter of 2019.
  • Net sales were USD 402 million in the U.S. and USD 363 million in the rest of the world.
  • Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
  • DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan.

Sports Anchor And Multiple Myeloma Patient Rod Gilmore Joins Amgen's Myeloma MVP™ Team

Retrieved on: 
Tuesday, October 15, 2019
Baseball players, Baseball, Multiple myeloma, RTT, Don Baylor, Monoclonal antibodies

Experience the interactive Multichannel News Release here:

Key Points: 
  • Experience the interactive Multichannel News Release here:
    College football anchor Rod Gilmore, who was diagnosed with multiple myeloma in July 2016, is partnering with Amgen Oncology as part of this year's Myeloma MVP team.
  • Gilmore joins baseball Hall of Famer Dave Winfield, and Don Baylor Jr., who helped launch Myeloma MVP in 2018.
  • "The Myeloma MVP program offers tools for patients and their support teams that can help them work together to create a personalized plan for managing multiple myeloma."
  • Renowned college football analyst and former collegiate athlete Rod Gilmore was diagnosed with multiple myeloma in July 2016.

NanOlogy to Present Interim Data for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas with Local Injection of NanoPac®

Retrieved on: 
Tuesday, October 15, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Gastrointestinal cancer, Pancreatic cancer, RTT, Monoclonal antibodies

The Phase 2a dose-rising and expansion pancreatic cancer trial is evaluating the safety and preliminary efficacy of NanoPac delivered intratumorally by EUS-FNI in patients with locally advanced pancreatic cancer.

Key Points: 
  • The Phase 2a dose-rising and expansion pancreatic cancer trial is evaluating the safety and preliminary efficacy of NanoPac delivered intratumorally by EUS-FNI in patients with locally advanced pancreatic cancer.
  • The study is currently enrolling in the dose expansion phase of the study and patients are receiving two intratumoral injections of NanoPac four weeks apart.
  • In 2019, an estimated 57,000 new cases of pancreatic cancer will be diagnosed in the U.S. and 46,000 people will die from the disease.
  • If successful, NanOlogy may provide a local therapy to assist in the treatment of patients with pancreatic cancer.

Global Monoclonal Antibodies Industry

Retrieved on: 
Monday, October 14, 2019
Medical specialties, Medicine, Immunology, Monoclonal antibodies, Biotechnology, Immune system

US Monoclonal Antibodies Market Share (in %) by Company: 2019 &

Key Points: 
  • US Monoclonal Antibodies Market Share (in %) by Company: 2019 &
    and Projections in US$ Million by Indication: 2018 to 2025
    and Projections in US$ Million by Source: 2018 to 2025
    Forecasts in US$ Million by Application: 2018 to 2025
    Forecasts in US$ Million by Indication: 2018 to 2025
    by Indication in US$ Million: 2009-2017
    Table 48: Monoclonal Antibodies Market in Canada: Percentage
    Share Breakdown of Sales by Indication for 2009, 2019, and 2025
    Forecasts in US$ Million by Source: 2018 to 2025
    by Source in US$ Million: 2009-2017
    Table 51: Monoclonal Antibodies Market in Canada: Percentage
    Share Breakdown of Sales by Source for 2009, 2019, and 2025
    Demand Analysis in US$ Million by Application: 2018 to 2025
    Table 53: Monoclonal Antibodies Market in Canada: Summarization
    Table 55: Japanese Market for Monoclonal Antibodies: Annual
    Table 56: Monoclonal Antibodies Market in Japan: Historic Sales
    Table 58: Japanese Market for Monoclonal Antibodies: Annual
    Table 59: Monoclonal Antibodies Market in Japan: Historic Sales
    Monoclonal Antibodies in US$ Million by Application: 2018 to
    China in US$ Million by Indication: 2009-2017
    Table 66: Chinese Monoclonal Antibodies Market by Indication:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    China in US$ Million by Source: 2009-2017
    Table 69: Chinese Monoclonal Antibodies Market by Source:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    in US$ Million by Region/Country: 2018-2025
    Table 74: Monoclonal Antibodies Market in Europe: A Historic
    Forecasts in US$ Million by Indication: 2018-2025
    Forecasts in US$ Million by Source: 2018-2025
    Opportunity in US$ Million by Application: 2018-2025
    Table 83: Monoclonal Antibodies Market in Europe: Summarization
    Table 85: Monoclonal Antibodies Market in France by Indication:
    in US$ Million by Indication: 2009-2017
    Table 88: Monoclonal Antibodies Market in France by Source:
    in US$ Million by Source: 2009-2017
    France in US$ Million by Application: 2018-2025
    in US$ Million by Application: 2009-2017
    Table 93: French Monoclonal Antibodies Market Share Analysis: A
    17-Year Perspective by Application for 2009, 2019, and 2025
    Table 94: Monoclonal Antibodies Market in Germany: Recent Past,
    in US$ Million by Indication: 2009-2017
    Table 97: Monoclonal Antibodies Market in Germany: Recent Past,
    in US$ Million by Source: 2009-2017
    Table 100: Monoclonal Antibodies Market in Germany: Annual
    Italy in US$ Million by Indication: 2009-2017
    Table 105: Italian Monoclonal Antibodies Market by Indication:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    Italy in US$ Million by Source: 2009-2017
    Table 108: Italian Monoclonal Antibodies Market by Source:
    Percentage Breakdown of Sales for 2009, 2019, and 2025
    Table 112: United Kingdom Market for Monoclonal Antibodies:
    Table 113: Monoclonal Antibodies Market in the United Kingdom:
    Table 115: United Kingdom Market for Monoclonal Antibodies:
    Table 116: Monoclonal Antibodies Market in the United Kingdom:
    Monoclonal Antibodies in US$ Million by Application: 2018 to
    Forecasts in US$ Million by Indication: 2018 to 2025
    by Indication in US$ Million: 2009-2017
    Table 123: Monoclonal Antibodies Market in Spain: Percentage
    Share Breakdown of Sales by Indication for 2009, 2019, and 2025
    Forecasts in US$ Million by Source: 2018 to 2025
    by Source in US$ Million: 2009-2017
    Table 126: Monoclonal Antibodies Market in Spain: Percentage
    Share Breakdown of Sales by Source for 2009, 2019, and 2025
    Demand Analysis in US$ Million by Application: 2018 to 2025
    Table 128: Monoclonal Antibodies Market in Spain: Summarization
    Projections in US$ Million by Indication: 2018 to 2025
    Projections in US$ Million by Source: 2018 to 2025
    Table 134: Monoclonal Antibodies Market in Russia by Source: A
    Forecasts in US$ Million by Application: 2018 to 2025
    Estimates and Forecasts in US$ Million by Indication: 2018-2025
    Estimates and Forecasts in US$ Million by Source: 2018-2025
    Market Opportunity in US$ Million by Application: 2018-2025
    Table 146: Monoclonal Antibodies Market in Rest of Europe:
    and Forecasts in US$ Million by Region/Country: 2018-2025
    Table 149: Monoclonal Antibodies Market in Asia-Pacific:
    Scenario in US$ Million by Indication: 2009-2017
    Scenario in US$ Million by Source: 2009-2017
    in Asia-Pacific in US$ Million by Application: 2018-2025
    Review in US$ Million by Application: 2009-2017
    Analysis: A 17-Year Perspective by Application for 2009, 2019,
    Table 160: Monoclonal Antibodies Market in Australia: Recent
    Analysis in US$ Million by Indication: 2009-2017
    Table 163: Monoclonal Antibodies Market in Australia: Recent
    Analysis in US$ Million by Source: 2009-2017
    Table 166: Monoclonal Antibodies Market in Australia: Annual
    Retrospect in US$ Million by Application: 2009-2017
    Forecasts in US$ Million by Indication: 2018 to 2025
    by Indication in US$ Million: 2009-2017
    Table 171: Monoclonal Antibodies Market in India: Percentage
    Share Breakdown of Sales by Indication for 2009, 2019, and 2025
    Forecasts in US$ Million by Source: 2018 to 2025
    by Source in US$ Million: 2009-2017
    Table 174: Monoclonal Antibodies Market in India: Percentage
    Share Breakdown of Sales by Source for 2009, 2019, and 2025
    Demand Analysis in US$ Million by Application: 2018 to 2025
    Table 176: Monoclonal Antibodies Market in India: Summarization
    Table 178: Monoclonal Antibodies Market in South Korea: Recent
    Analysis in US$ Million by Indication: 2009-2017
    Table 181: Monoclonal Antibodies Market in South Korea: Recent
    Analysis in US$ Million by Source: 2009-2017
    Table 184: Monoclonal Antibodies Market in South Korea: Recent
    Analysis in US$ Million by Application: 2009-2017
    for Monoclonal Antibodies in US$ Million by Application: 2018
    by Region/Country in US$ Million: 2018-2025
    Percentage Breakdown of Sales by Region/Country: 2009, 2019,
    Latin America in US$ Million by Indication: 2009-2017
    Indication: Percentage Breakdown of Sales for 2009, 2019, and
    Latin America in US$ Million by Source: 2009-2017
    Source: Percentage Breakdown of Sales for 2009, 2019, and 2025
    in US$ Million by Application: 2009-2017
    and Forecasts in US$ Million by Indication: 2018-2025
    and Forecasts in US$ Million by Source: 2018-2025
    Opportunity in US$ Million by Application: 2018-2025
    Table 215: Monoclonal Antibodies Market in Argentina:
    Scenario in US$ Million by Indication: 2009-2017
    Table 220: Monoclonal Antibodies Market in Brazil by Source:
    Scenario in US$ Million by Source: 2009-2017
    in Brazil in US$ Million by Application: 2018-2025
    Review in US$ Million by Application: 2009-2017
    Analysis: A 17-Year Perspective by Application for 2009, 2019,
    Table 226: Monoclonal Antibodies Market in Mexico: Recent Past,
    Analysis in US$ Million by Indication: 2009-2017
    Table 229: Monoclonal Antibodies Market in Mexico: Recent Past,
    Analysis in US$ Million by Source: 2009-2017
    Table 232: Monoclonal Antibodies Market in Mexico: Annual Sales
    in US$ Million by Application: 2009-2017
    Estimates and Projections in US$ Million by Indication: 2018 to
    Estimates and Projections in US$ Million by Source: 2018 to
    Demand Forecasts in US$ Million by Application: 2018 to 2025
    of Latin America by Application: 2009 VS 2019 VS 2025
    Estimates and Forecasts in US$ Million by Region/Country:
    Estimates and Forecasts in US$ Million by Indication: 2018 to
    Market by Indication in US$ Million: 2009-2017
    Table 249: Monoclonal Antibodies Market in the Middle East:
    Percentage Share Breakdown of Sales by Indication for 2009,
    Estimates and Forecasts in US$ Million by Source: 2018 to 2025
    Market by Source in US$ Million: 2009-2017
    Table 252: Monoclonal Antibodies Market in the Middle East:
    Percentage Share Breakdown of Sales by Source for 2009, 2019,
    Quantitative Demand Analysis in US$ Million by Application:
    Table 254: Monoclonal Antibodies Market in the Middle East:
    Table 256: Iranian Market for Monoclonal Antibodies: Annual
    Table 257: Monoclonal Antibodies Market in Iran: Historic Sales
    Table 259: Iranian Market for Monoclonal Antibodies: Annual
    Table 260: Monoclonal Antibodies Market in Iran: Historic Sales
    Monoclonal Antibodies in US$ Million by Application: 2018 to
    Forecasts in US$ Million by Indication: 2018-2025

CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

Retrieved on: 
Monday, October 14, 2019
Autoimmune diseases, Monoclonal antibodies, Mesoblast, Regenerative biomedicine, Draft:BrainStorm Cell Therapeutics

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

Key Points: 
  • CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
  • CymaBay is currently enrolling patients in a global, Phase 3 registration study of seladelpar for PBC.
  • This study is a 52-week, placEbo-coNtrolled, randomized, pHAse 3 study to evaluate the safety aNd effiCacy of sEladelpar (ENHANCE) in patients with PBC.
  • Seladelpar received orphan designation for PBC from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA).

Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Saturday, October 12, 2019
Organ systems, Medical specialties, Monoclonal antibodies, Immunosuppressants, Immunology, RTT, Eli Lilly and Company, Psoriasis, Ixekizumab, Venereology

Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.

Key Points: 
  • Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain.
  • Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.
  • "We're pleased to see positive results for Taltz in pediatric patients.
  • 81 percent of patients treated with Taltz achieved sPGA 0,1 compared to 11 percent of patients treated with placebo.

CytoDyn to Present at The MicroCap Rodeo Conference

Retrieved on: 
Friday, October 11, 2019
Hepatotoxins, Drugs, Clinical medicine, RTT, Medicine, Azides, Zidovudine, Management of HIV/AIDS, Monoclonal antibodies, Sacituzumab govitecan

A live webcast of the presentation will be available at CytoDyn Presentation at MicroCap Rodeo or https://www.cytodyn.com see Latest Events.

Key Points: 
  • A live webcast of the presentation will be available at CytoDyn Presentation at MicroCap Rodeo or https://www.cytodyn.com see Latest Events.
  • The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • CytoDyn is therefore conducting aPhase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.

TNF Alpha Inhibitors Market Expected to Grow by 3.6% During the Forecast Period, 2019-2025

Retrieved on: 
Friday, October 11, 2019
Drugs, Medical specialties, TNF inhibitors, Immunosuppressants, Immunology, Monoclonal antibodies, Biotechnology, Janssen Biotech, Infliximab, Adalimumab, Etanercept, Tumor necrosis factor alpha

Overview of the Global TNF Alpha Inhibitors Market Research:

Key Points: 
  • Overview of the Global TNF Alpha Inhibitors Market Research:
    The author's market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019-2025.
  • Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market.
  • According to the author analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period.
  • Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019-2025.